Categories Analysis, Industrials, U.S. Markets News

What are GE’s priorities for 2019?

General Electric’s (GE) shares were down 7.5% in mid-day trade on Wednesday, a day after J.P. Morgan analyst Stephen Tusa said his price target of $6 was looking generous, following GE’s gloomy forecast for this year.

At the J.P. Morgan conference on Tuesday, GE CEO Lawrence Culp Jr. indicated that the company’s industrial free cash flow will be negative in 2019.

GE strategic priorities for 2019
(Image Courtesy: GE Power)

At the conference, GE laid out its priorities for 2019. The topmost is to improve its financial position. The company’s decision to sell its biopharma business to Danaher for $21 billion is part of these efforts. GE also reduced its dividend and is undertaking industrial dispositions worth $20 billion. The firm aims to prioritize cash generation in every business.

The second priority is to strengthen its businesses, starting with Power. The business has been facing non-operational headwinds along with execution challenges in terms of project underwriting and cost over-runs. GE plans to take additional actions in 2019 to right-size Power’s footprint.

Also read: GE’s stock soars around 15% on news of Biopharma business sale to Danaher

GE’s initial thoughts for 2019 include an expectation for organic revenue growth in the low to mid-single digit range, and strong performance in Aviation and Renewables. The company expects organic growth in the low to mid-single digit range in Healthcare. Power is expected to be down in a flat to slightly down market.

GE is expected to provide an outlook on March 14, 2019 and the stock is likely to experience some volatility at that time.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top